Sappi: corporate overview January 2010

2 3 Fine Paper mills 5 Forest Products mills 10 Sales offices 1 Sales office 9 Fine Paper mills 17 Sales offices 1 Fine Paper mill JV 4 Sales offices 1 Sales office 2 Fine Paper mills 1 Specialty Paper mill 5 Sales offices 1 Sales office Group overview

3  We are the world’s leading producer of high quality coated fine paper used in printing everything from art books to quality magazines to wine labels. (USA, Europe, South Africa, China JV)  We also produce a range of business paper, coated and uncoated speciality paper and casting release paper. (USA, Europe, SA)  We are the largest and lowest cost producer of the chemical cellulose pulp used to produce viscose fiber. (SA – 100% export)  We manufacture on four continents and have 40 sales offices around the globe, supplying paper and pulp to customers in over 100 countries.  We employ over 15,600 people and achieved an annual turnover of US$5.369 million (2009)  We are listed on the stock exchanges of Johannesburg and New York. Sappi Limited - who are we today?

4 Fine paper mills in South Africa Enstra Mill 200,000 tons uncoated fine paper 105,000 tons pulp Stanger Mill 110,000 tons coated fine paper and tissue 60,000 tons pulp Adamas Mill 40,000 tons uncoated fine paper Total fine paper capacity in SA: 350,000 tons/year

5 Forest Product operations in Southern Africa Plantations in Mpumalanga, Kwa Zulu Natal and Swaziland: 527,000ha land - 380,000ha planted Cape Kraft 60,000 tons kraft 510,000 tons pulp 240,000 tons kraft 140,000 tons newsprint Ngodwana 800,000 tons chemical cellulose (dissolving pulp) Saiccor 390,000 tons kraft 350,000 tons pulp Tugela

6 Corporate Social Responsibility: community development Various projects: Braamfontein rejuvenation Refurbished Sappi Head Office and Piazza

7 TB in Sappi

8

9 Sappi Manage TB  Centre of excellence:  Sappi Sister obtain the sputum sample  Sappi Sister submit sample to the DoH lab  Sappi Sister receive the results within 3-4 days  DoH liaise with Sappi sister regarding treatment  Sappi Sister initiate DOT and monitor the patient for duration of treatment.  Partnership between Sappi and DoH

10  Situation in most of the Units:  Patient refer to local clinic with long waiting lists – loose a day of work  Wait weeks for results – numerous phone calls, staff turnover  Patient to clinic where treatment is initiated – little to no communication with DoH  DOT: Never sure what DoH has implemented - Sappi implement another system. Cause confusion.  Repeat medication collection: patient loose each time a day from work.  Sputum results: Again communication breakdown

11  Action required:  Sappi to initiate partnership with DoH.  Training of health personnel  Re-launch TB awareness programmes  Implement DOT  TB testing cumbersome and time consuming  Clinics safer places

12

13

14